Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of LTG-305 in Healthy Volunteers
NCT06554574Phase 1Completed
- Sponsor
- Latigo Biotherapeutics
- Start
- Sep 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LTG-305 in chronic pain (5 arms), sponsored by Latigo Biotherapeutics. Primary endpoints: Safety and tolerability of single and multiple ascending oral doses and Pharmacodynamics of LTG-305. Started Sep 2024; status: completed.
02
Drugs
LTG-305
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT06554574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06554574.